Browse medicines, page 3 of 34

Use listed on the medicine record

temporarily relieves these symptoms due to hay fever or other upper respiratory allergies: sneezing runny nose itchy, watery eyes itchy throat

Use listed on the medicine record

• Aids in the removal of phlegm, mucus, or other secretions associated with occasional sore mouth. • For temporary use in cleansing minor wounds or minor gum inflammation resulting from minor dental procedures, dentures, orthodontic appliances, accidental injury, or other irritations of the mouth and gums. • For temporary use to cleanse canker sores. • Assists in the removal of foreign material from minor oral wounds.

Use listed on the medicine record

INDICATIONS: Based on a review of a related drug by the National Research Council and subsequent FDA classification for that drug, the indications are as follows: “Possibly” Effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis; bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris,…

Use listed on the medicine record

LUPRON DEPOT 3.75 mg is a gonadotropin-releasing hormone (GnRH) agonist indicated for: Endometriosis Management of endometriosis, including pain relief and reduction of endometriotic lesions. ( 1.1 ) In combination with a norethindrone acetate for initial management of the painful symptoms of endometriosis and for management of recurrence of symptoms. ( 1.1 ) Limitations of Use: The total duration of therapy with LUPRON DEPOT 3.75 mg plus add-back therapy should not exceed 12 months due to concerns about adverse impact on bone mineral density.

Use listed on the medicine record

Acute and chronic treatment of patients with an inborn error of metabolism which results in a secondary carnitine deficiency

Use listed on the medicine record

Heavy menstrual bleeding for up to 5 years

Use listed on the medicine record

Vertigo associated with diseases affecting the vestibular system

Use listed on the medicine record

The risk for weight regain after prior weight loss

Use listed on the medicine record

INDICATIONS Penicillamine tablets are indicated in the treatment of Wilson's disease, cystinuria, and in patients with severe, active rheumatoid arthritis who have failed to respond to an adequate trial of conventional therapy. Available evidence suggests that penicillamine tablets are not of value in ankylosing spondylitis. Wilson’s Disease Wilson's disease (hepatolenticular degeneration) results from the interaction of an inherited defect and an abnormality in copper metabolism.

Use listed on the medicine record

And pediatric patients ages 3 years and older for the reversal of soft-tissue anesthesia, i

Use listed on the medicine record

The treatment of adult patients

Use listed on the medicine record

Moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause

Use listed on the medicine record

Postoperative pain

Use listed on the medicine record

Coronavirus disease 2019

Use listed on the medicine record

Relief of the signs and symptoms of rheumatoid arthritis, osteoarthritis and related rheumatic disorder

Use listed on the medicine record

Serum phosphorus

Use listed on the medicine record

Pulmonary arterial hypertension

Use listed on the medicine record

Insomnia characterized by difficulties with sleep onset and/or sleep maintenance

Use listed on the medicine record

Testosterone replacement therapy

Use listed on the medicine record

The signs and symptoms of idiopathic Parkinson's disease

Use listed on the medicine record

Moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to one or more TNF blockers

Use listed on the medicine record

Previously untreated mantle cell lymphoma (MCL) who are ineligible for autologous hematopoietic stem cell transplantation

Use listed on the medicine record

none

Use listed on the medicine record

Regulating immunity

Use listed on the medicine record

Wakefulness

Use listed on the medicine record

HIV-1 infection

Use listed on the medicine record

Auranofin Capsules (auranofin) is indicated in the management of adults with active classical or definite rheumatoid arthritis (ARA criteria) who have had an insufficient therapeutic response to, or are intolerant of, an adequate trial of full doses of one or more nonsteroidal anti-inflammatory drugs. Auranofin Capsules should be added to a comprehensive baseline program, including non-drug therapies. Unlike anti-inflammatory drugs, Auranofin Capsules does not produce an immediate response.

Use listed on the medicine record

Moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more tumor necrosis fac

Use listed on the medicine record

Hypertension, to lower blood pressure

Use listed on the medicine record

Dysfunctions associated with hyperprolactinemia including amenorrhea with or without galactorrhea, infertility or hypogonadism

Use listed on the medicine record

Regul Oil Cleansing Cream indications

Use listed on the medicine record

The following infections caused by susceptible Gram-negative microorganisms

Use listed on the medicine record

The treatment of adult patients

Use listed on the medicine record

Treatment of patients with advanced prostate cancer

Use listed on the medicine record

The topical treatment of moderate to severe chronic hand eczema

Use listed on the medicine record

Dimethyl fumarate delayed-release capsules are indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. Dimethyl fumarate delayed-release capsules are indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. ( 1 )

Use listed on the medicine record

VUMERITY is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. VUMERITY is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. ( 1 )

Use listed on the medicine record

The treatment of patients

Use listed on the medicine record

The short-term treatment

Use listed on the medicine record

Step1: After using the basic lotion Step2: Apply appropriate amount to the palm, smear on the whole face, neck and other easily exposed parts Step3: Apply evenly and gently so that it absorbs into a film

Use listed on the medicine record

①Take out a bottle of essence from the box ②Unscrew the top cap and squeeze the essence intothe palm of your hand ③Apply evenly on the face and neck,gently massage until fully moisturized

Use listed on the medicine record

The topical treatment of atopic dermatitis

Use listed on the medicine record

Locally confined Stage B 2 -C and Stage D 2 metastatic carcinoma of the prostate

Use listed on the medicine record

Hypertension

Use listed on the medicine record

Thrombocytopenia

Use listed on the medicine record

Type I hyperlipoproteinemia, who have elevations of chylomicrons and plasma triglycerides, but who have normal levels of very low density li

Use listed on the medicine record

Severe hypoglycemia

Use listed on the medicine record

Chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma

Use listed on the medicine record

VASCEPA ® (icosapent ethyl) is indicated: as an adjunct to maximally tolerated statin therapy to reduce the risk of myocardial infarction, stroke, coronary revascularization, and unstable angina requiring hospitalization in adult patients with elevated triglyceride (TG) levels (≥ 150 mg/dL) and established cardiovascular disease or diabetes mellitus and 2 or more additional risk factors for cardiovascular disease. as an adjunct to diet to reduce TG levels in adult patients with severe (≥ 500 mg/dL) hypertriglyceridemia.

Use listed on the medicine record

Endocrine-resistant, PIK3CA -mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative

Use listed on the medicine record

• helps prevent sunburn • if used as directed with other sun protection measures (see Directions). Decreases the risk of skin cancer and early skin aging caused by the sun.

Use listed on the medicine record

Tear off the patch,Stick it 5 to 8 centimeters belowthe base of your palm, Place the product on the back of your neck